Medicare Coverage of Weight-Loss Drugs

Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) were originally created to treat Type 2 diabetes, but they have a beneficial side effect: They suppress the urge to eat, and patients typically lose significant amounts of weight as a result.

In light of the fact that 41% of Americans have obesity and another 35% are considered overweight, demand has surged for these medicines. All that demand, however, has sparked a debate on how to pay for the expensive drugs and if Medicare should cover them.

None of these three medications costs less than $10,000 a year. The list prices (before or without insurance) are: Medicare Coverage of Weight

The information being provided is strictly as a courtesy. When you link to any of these websites provided herein, Brown & Stromecki Agency, Inc. makes no representation as to the completeness or accuracy of information provided at these sites. Nor is the company liable for any direct or indirect technical or system issues or any consequences arising out of your access to or your use of third-party technologies, sites, information, and programs made available through this site.

Cambridge’s Form CRS (Customer Relationship Summary)

Brown & Stromecki Agency, Inc.
4313 South Buffalo Street
Orchard Park, New York 14127
Phone/Text: 716-662-4461
Fax: 716-662-2525

Brown & Stromecki